Table 3.
Protection against ultimate severe COVID-19 disease by the receipt of complete regimens of vaccines *.
| Ultimately Severe Cases | Matched Controls | Protective Effectiveness (PE) % (95% Confidence Interval, CI) | ||||||
|---|---|---|---|---|---|---|---|---|
| Vaccines | Vaccinees | Non-Vaccinees | Vaccinees | Non-Vaccinees | Crude PE | p-Value | Adjusted † PE | p-Value |
| Any vaccine ‡ | 3 | 27 | 34 | 70 | 86 (32, 97) |
0.015 | 85 (27, 97) |
0.019 |
| Serum Institute of India (ChAdOx1 nCoV-19) § | 2 | 27 | 12 | 66 | 85 (−39, 98) |
0.095 | 86 (−23, 98) |
0.076 |
| Sinopharm (Vero Cell-Inactivated) || | 1 | 26 | 12 | 68 | 79 (−77, 98) |
0.151 | 75 (−124, 97) |
0.214 |
| Moderna (mRNA-1273) ¶ | 0 | 26 | 8 | 64 | 100 (−Inf, 100) |
0.998 | 100 (−Inf, 100) |
0.999 |
* Received a second dose of vaccine at least 14 days before presentation. † Adjusted by covariates gender and smoking status are significantly associated at p < 0.05 in the bivariate conditional logistic regression model. ‡ Any vaccine (Serum Institute of India (ChAdOx1 nCoV-19), Sinopharm (Vero Cell-Inactivated), Moderna (mRNA-1273), and Sinovac (Vero Cell-Inactivated)). § Participants who received only the Serum Institute of India-ChAdOx1 nCoV-19 vaccine or non-vaccinees (severe cases = 29; matched controls = 78). || Participants who received only Sinopharm (Vero Cell-Inactivated) vaccine or non-vaccines (severe cases = 28; matched controls = 80); 1 case excluded since no matched control was available. ¶ Participants who received only the Moderna mRNA-1273 vaccine or non-vaccinees (severe cases = 27; matched controls = 72); 1 case excluded since no matched control was available.